Survival and cardiac toxicity in patients with HER2‐positive, metastatic breast cancer treated with trastuzumab in routine clinical practice

Aims We sought to describe survival outcomes and toxicities of trastuzumab in real‐world patients with HER2‐positive, metastatic breast cancer (MBC) and compare these to a recent systematic review of clinical trials. Methods We searched the medical records of three Sydney cancer centers for patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Asia-Pacific journal of clinical oncology 2020-02, Vol.16 (1), p.34-38
Hauptverfasser:	Vasista, Anuradha, Ryan, Luke, Naher, Sayeda, Moylan, Eugene, Stockler, Martin R, Wilcken, Nicholas, Kiely, Belinda E
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents, Immunological - adverse effects Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - pathology cardiac toxicity Cardiotoxicity - etiology Cardiotoxicity - mortality Cardiotoxicity - pathology Clinical trials ErbB-2 protein Female Heart HER2‐positive metastatic breast cancer Humans Immunotherapy Medical records Metastases Metastasis Middle Aged Monoclonal antibodies Patients Practice Patterns, Physicians' - statistics & numerical data Receptor, ErbB-2 - metabolism Survival Survival Rate survival times Systematic review Targeted cancer therapy Toxicity Trastuzumab Trastuzumab - adverse effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!